Cargando…
Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins
Targeted genome editing has a great therapeutic potential to treat disorders that require protein replacement therapy. To develop a platform independent of specific patient mutations, therapeutic transgenes can be inserted in a safe and highly transcribed locus to maximize protein expression. Here,...
Autores principales: | Pavani, Giulia, Laurent, Marine, Fabiano, Anna, Cantelli, Erika, Sakkal, Aboud, Corre, Guillaume, Lenting, Peter J., Concordet, Jean-Paul, Toueille, Magali, Miccio, Annarita, Amendola, Mario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391635/ https://www.ncbi.nlm.nih.gov/pubmed/32728076 http://dx.doi.org/10.1038/s41467-020-17552-3 |
Ejemplares similares
-
Author Correction: Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins
por: Pavani, Giulia, et al.
Publicado: (2020) -
Genome Editing for β-Hemoglobinopathies: Advances and Challenges
por: Frati, Giacomo, et al.
Publicado: (2021) -
Base and Prime Editing Technologies for Blood Disorders
por: Antoniou, Panagiotis, et al.
Publicado: (2021) -
Editorial: Mutation-Specific Gene Editing for Blood Disorders
por: Lederer, Carsten Werner, et al.
Publicado: (2021) -
CRISPRthripsis: The Risk of CRISPR/Cas9-induced Chromothripsis in Gene Therapy
por: Amendola, Mario, et al.
Publicado: (2022)